CAS 1258417-54-7

ACT-389949

CAS: 1258417-54-7

ACT-389949: Potent, selective FPR2/ALX agonist; EC50 3 nM; potential inflammatory disorder treatment.

Fórmula: C₂₀H₁₈F₂N₆O₃

Pureza: 99.4%

Forma y color: Solid

Peso molecular: 428.39

Ref: TM-T10242

N-(2-((4-(1,1-Difluoroethyl)oxazol-2-yl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(m-tolyl)oxazole-4-carboxamide

CAS: 1258417-54-7

Fórmula: C₂₀H₁₈F₂N₆O₃

Pureza: 98%

Forma y color: Solid

Peso molecular: 428.3921

Ref: IN-DA01N18B

N-(2-((4-(1,1-Difluoroethyl)Oxazol-2-Yl)Methyl)-2H-1,2,3-Triazol-4-Yl)-2-Methyl-5-(M-Tolyl)Oxazole-4-Carboxamide

CAS: 1258417-54-7

N-(2-((4-(1,1-Difluoroethyl)Oxazol-2-Yl)Methyl)-2H-1,2,3-Triazol-4-Yl)-2-Methyl-5-(M-Tolyl)Oxazole-4-Carboxamide

Pureza: 98%

Peso molecular: 428.39g/mol

Ref: 54-PC108497

ACT-389949

CAS: 1258417-54-7

ACT-389949

Pureza: ≥95%

Peso molecular: 428.39g/mol

Ref: 54-BUP00479

ACT-389949

CAS: 1258417-54-7

ACT-389949 is a novel small molecule that has been shown to be a potent inhibitor of neutrophil recruitment. It has been shown to inhibit the chemotaxis of neutrophils and leukocytes in vitro by binding to granule proteins and preventing their release. ACT-389949 is an orally active, potent, selective, and reversible inhibitor of neutrophil recruitment with a terminal half-life of approximately 24 hours. The pharmacodynamics of this drug are dose-dependent with an EC50 value at the lower end of the therapeutic window. This profile may explain why it is effective in patients who have been exposed to other drugs that are ineffective due to resistance. In addition, ACT-389949 does not induce any known inflammatory cytokines or act as an immunosuppressant.

Fórmula: C₂₀H₁₈F₂N₆O₃

Pureza: Min. 95%

Peso molecular: 428.4 g/mol

Ref: 3D-IAC41754